Search This Blog

Wednesday, October 28, 2026

Coherus interim Phase 1b: 75% confirmed ORR in esophageal squamous cell carcinoma

 

Coherus Oncology announces interim Phase 1b TREGCHECK data showing tagmokitug plus toripalimab achieves a 75% confirmed ORR in esophageal squamous cell carcinoma

  • Tagmokitug plus toripalimab achieved a 75% confirmed overall response rate in first-line esophageal squamous cell carcinoma.
  • Coherus will expand both first-line and second-line esophageal squamous cell carcinoma cohorts based on these interim results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)